LINC01116 and prostate cancer: The results from Beaver et al. supported an oncogenic function for LINC01116 in PC-3 cells when it was disrupted through the CRISPR/CAS9 method and confirmed knockdown of LINC01116 with siRNA decreased proliferation of prostate cancer cells [28].